Related Experiment Video
Updated: Mar 28, 2026
06:19
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
1.9K
Infliximab eye drops treatment in corneal neovascularization
1Department of Cellular and Molecular Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Journal of Medicine and Life
|December 15, 2015
Summary
Topical infliximab, a tumor necrosis factor-alpha (TNF-a) monoclonal antibody, effectively treated corneal neovascularization in a rabbit model. This offers a potential new therapy for this sight-threatening condition.
Area of Science:
- Ophthalmology
- Immunology
- Regenerative Medicine
Background:
- Corneal neovascularization (CNV) is a significant cause of vision loss.
- CNV can result from various insults including chemical burns, ischemia, infection, trauma, and inflammation.
- Current treatments for CNV have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy of topical infliximab in treating corneal neovascularization.
- To assess the anti-angiogenic potential of tumor necrosis factor-alpha (TNF-a) inhibition in the cornea.
Main Methods:
- A rabbit model of corneal neovascularization was established.
- Infliximab, a TNF-a monoclonal antibody, was administered topically.
- Corneal neovascularization was quantified and analyzed post-treatment.
Main Results:
- Topical infliximab significantly reduced corneal neovascularization.
- Infliximab demonstrated potent anti-angiogenic effects in the corneal model.
- No significant adverse effects were observed with topical application.
Conclusions:
- Topical infliximab is a promising therapeutic agent for corneal neovascularization.
- Targeting TNF-a offers a viable strategy for managing CNV.
- Further clinical studies are warranted to translate these findings to human patients.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
740
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
740
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
664
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
664
01:23Ophthalmic Drug Delivery Systems
212
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
212
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
624
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
624